SPY336.83-0.61 -0.18%
DIA279.42-0.62 -0.22%
IXIC11,042.50+30.27 0.27%

Supernus Pharma Reports Phase 3 P301 Trial Of SPN-810 For Treatment Of IA In ADHD Patients 6-11 Did Not Meet Primary Endpoint

Benzinga · -